Last edition
News about "ALYGLO"
GC Biopharma Rolls Out ALYGLO for Treatment of Primary Humoral Immunodeficiency
ALYGLO, an immune globulin formulation, has met the primary endpoints for both safety and efficacy as established by the FDA-recommended guidelines in our Phase 3 clinical trials.
ALYGLO | 09/09/2024 | By Aishwarya | 406
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members